Insider · CIK 0001577873
Alan Colman
Files at VNRX (VOLITIONRX LTD). First filing -, latest -.
Alan Colman files SEC Form 4 as director at VNRX (VOLITIONRX LTD). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Alan Colman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | VNRX VOLITIONRX LTD | AGrant or award Common Stock | +12,000 | $0.00 | $0 | 257,364 | Jan 23, 2026 |
| Mar 1, 2025 | VNRX VOLITIONRX LTD | AGrant or award Common Stock | +14,840 | $0.00 | $0 | 245,364 | Mar 4, 2025 |
| Jan 29, 2025 | VNRX VOLITIONRX LTD | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | - | - | 0 | Jan 31, 2025 |
| Jan 29, 2025 | VNRX VOLITIONRX LTD | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | - | - | 25,000 | Jan 31, 2025 |
| Dec 1, 2024 | VNRX VOLITIONRX LTD | AGrant or award Common Stock | +12,972 | $0.00 | $0 | 230,524 | Dec 3, 2024 |
Questions about Alan Colman
Answered from the filings on this page, as of the latest one.
Is Alan Colman buying or selling?
Alan Colman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Alan Colman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Alan Colman has 0.
Where does Alan Colman file Form 4?
Alan Colman has filed Form 4 at VNRX (VOLITIONRX LTD). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.